Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00107120
Status:
COMPLETED
Last Update Posted:
2012-04-06
First Post:
2005-04-05
Brief Title:
The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
Sponsor:
Forest Laboratories
Organization:
Forest Laboratories
Study Overview
Official Title:
A Double-blind Flexible Dose Study of Escitalopram in Pediatric Patients With Major Depressive Disorder
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Depression affects approximately 25 of children and 8 of adolescents Escitalopram is the S-enantiomer of citalopram Both escitalopram and citalopram are selective serotonin reuptake inhibitors SSRIs and are used to treat depression in adults This study is designed to provide a systematic evaluation of the safety and efficacy of escitalopram in the treatment of depressed pediatric patients 12 to 17 years of age Patients completing the study will be eligible to enter an open-label extension study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None